Multifunctional Carrier Based on Halloysite/Laponite Hybrid Hydrogel for Kartogenin Delivery
A novel carrier system based on halloysite nanotubes (HNT), for the potential intraarticular delivery of kartogenin (KGN) by means laponite (Lap) hydrogel (HNT/KGN/Lap), is developed. The drug was first loaded into HNT, and the hybrid composite obtained was used as filler for laponite hydrogel. Both the filler and the hydrogel were thoroughly investigated by several techniques and the hydrogel morphology was imaged by transmission electron microscopy. Furthermore, the gelating ability of laponite in the presence of the filler and the rheological properties of the hybrid hydrogel were also investigated. The kinetic release of kartogenin from HNT and HNT/Lap hybrid hydrogel was studied both in physiological conditions and in ex vivo synovial fluid. In the last case, the kinetic results highlighted that HNT carrier can effectively release KGN in a sustained manner for at least 38 days. Finally, a preliminary biological assays showed that the HNT/KGN/Lap hybrid hydrogel did not exhibit any cytotoxic effect.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:10 |
|---|---|
| Enthalten in: |
ACS medicinal chemistry letters - 10(2019), 4 vom: 11. Apr., Seite 419-424 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Massaro, Marina [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 11.10.2023 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1021/acsmedchemlett.8b00465 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM296173274 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM296173274 | ||
| 003 | DE-627 | ||
| 005 | 20231225085250.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1021/acsmedchemlett.8b00465 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0987.xml |
| 035 | |a (DE-627)NLM296173274 | ||
| 035 | |a (NLM)30996773 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Massaro, Marina |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Multifunctional Carrier Based on Halloysite/Laponite Hybrid Hydrogel for Kartogenin Delivery |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 11.10.2023 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a A novel carrier system based on halloysite nanotubes (HNT), for the potential intraarticular delivery of kartogenin (KGN) by means laponite (Lap) hydrogel (HNT/KGN/Lap), is developed. The drug was first loaded into HNT, and the hybrid composite obtained was used as filler for laponite hydrogel. Both the filler and the hydrogel were thoroughly investigated by several techniques and the hydrogel morphology was imaged by transmission electron microscopy. Furthermore, the gelating ability of laponite in the presence of the filler and the rheological properties of the hybrid hydrogel were also investigated. The kinetic release of kartogenin from HNT and HNT/Lap hybrid hydrogel was studied both in physiological conditions and in ex vivo synovial fluid. In the last case, the kinetic results highlighted that HNT carrier can effectively release KGN in a sustained manner for at least 38 days. Finally, a preliminary biological assays showed that the HNT/KGN/Lap hybrid hydrogel did not exhibit any cytotoxic effect | ||
| 650 | 4 | |a Journal Article | |
| 700 | 1 | |a Buscemi, Gabriella |e verfasserin |4 aut | |
| 700 | 1 | |a Arista, Luca |e verfasserin |4 aut | |
| 700 | 1 | |a Biddeci, Giuseppa |e verfasserin |4 aut | |
| 700 | 1 | |a Cavallaro, Giuseppe |e verfasserin |4 aut | |
| 700 | 1 | |a D'Anna, Francesca |e verfasserin |4 aut | |
| 700 | 1 | |a Di Blasi, Francesco |e verfasserin |4 aut | |
| 700 | 1 | |a Ferrante, Angelo |e verfasserin |4 aut | |
| 700 | 1 | |a Lazzara, Giuseppe |e verfasserin |4 aut | |
| 700 | 1 | |a Rizzo, Carla |e verfasserin |4 aut | |
| 700 | 1 | |a Spinelli, Gaetano |e verfasserin |4 aut | |
| 700 | 1 | |a Ullrich, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a Riela, Serena |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t ACS medicinal chemistry letters |d 2010 |g 10(2019), 4 vom: 11. Apr., Seite 419-424 |w (DE-627)NLM19927455X |x 1948-5875 |7 nnns |
| 773 | 1 | 8 | |g volume:10 |g year:2019 |g number:4 |g day:11 |g month:04 |g pages:419-424 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1021/acsmedchemlett.8b00465 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 10 |j 2019 |e 4 |b 11 |c 04 |h 419-424 | ||